Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Earlier Diagnosis of Melanoma May Soon Become Possible Using T-Rays

By BiotechDaily International staff writers
Posted on 23 Sep 2013
Image: Layers of skin can be probed with terahertz rays in search of signs of skin cancer at its earliest stages of development (Photo courtesy of the [US] National Cancer Institute).
Image: Layers of skin can be probed with terahertz rays in search of signs of skin cancer at its earliest stages of development (Photo courtesy of the [US] National Cancer Institute).
New imaging technology has great potential to diagnose cancer at its earliest and most treatable stages.

Anis Rahman, PhD, president and chief technology officer of Applied Research & Photonics (Harrisburg, PA, USA), reported that malignant melanoma, the most lethal type of skin cancer, begins in pigment-producing cells located in the deepest part of the epidermis (the outer layer of the skin). Biochemical alterations are key characteristics of cancer occur in the melanocytes a long time before mole-like melanomas appear on the skin.

“Terahertz radiation is ideal for looking beneath the skin and detecting early signs of melanoma,” Dr. Rahman said. “T-rays are different from X-rays, which are ‘ionizing’ radiation that can cause damage. T-rays are a form of nonionizing radiation, like ordinary visible light, but they can be focused harmlessly below into the body and capture biochemical signatures of events like the start of cancer.”

T-rays occupy a position in the spectrum of electromagnetic radiation, which includes visible light and X-rays, between microwaves and infrared rays. One of the benefits of T-rays is that they penetrate only a few millimeters through skin, cloth, and other nonmetallic material.

Dr. Rahman’s research on T-rays was made through donated samples of human skin, suggesting that the technology could be valuable in diagnosing melanoma. In addition to developing T-rays for cancer diagnostics, Dr. Rahman’s team has effectively utilized them to measure the real-time absorption rates and penetration in the outer layer of skin of topically applied drugs—measurements that until now had not been possible.

Dr. Rahman presented his findings at a symposium held at the annual American Chemical Society (ACS) 2013 meeting, held September 11, 2013, in Indianapolis (IN, USA).

Related Links:
Applied Research & Photonics


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.